Completed PHASE3 INTERVENTIONAL 2-arm NCT01383460

Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure

Randomized Placebo-controlled Trial to Assess the Efficacy of Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO) in the Survival of Patients With Acute-on-chronic Liver Failure (ACLF)

Sponsor: Institute of Liver and Biliary Sciences, India

Conditions Acute on Chronic Hepatic Failure

Interventions Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO) Placebo

Updated 5 times since 2017 Last updated: Dec 4, 2016 Started: Jul 31, 2011 Primary completion: Jan 31, 2013 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute on Chronic Hepatic Failure, this trial is completed. The trial is conducted by Institute of Liver and Biliary Sciences, India and has accumulated 5 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institute of Liver and Biliary Sciences, India

Data source: Institute of Liver and Biliary Sciences, India

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Delhi, India